The NTCI treatment reduced the expression of the genes encoding fibrinogen chains and Factor X in the lungs and kidneys thereby potentially reducing the risk of DIC in sepsis, and by extension, in thrombophilia. The gene discussed is F10; the disease is Rare hereditary thrombophilia.